Clinical & Experimental Cardiology
Open Access
ISSN: 2155-9880
ISSN: 2155-9880
Department of Cardiovascular Medicine, Jiamusi University, Jiamus, China
Research Article
Dapagliflozin Protects Cardiomyocytes from H/R Injury by Regulating miR-124-3p
Author(s): Kaiyuan Cen, Xianglong Liang, Yuan Ding and Haibo Yu*
Background: Reperfusion therapy is one of the main methods for alleviating myocardial infarction. However, this treatment may cause injury to the myocardium, known as Hypoxia/Reoxygenation (H/R) injury. Dapagliflozin is a kind of novel hypoglycemic drug, but its role in modulating the H/R injury of cardiomyocytes has not been fully clarified.
Methods: The H/R model and MI rats were established. Reactive Oxygen Species (ROS) level was examined by 2’, 7’- Dichlorofluorescein-Diacetate (DCFH-DA) assay. The release of Lactate Dehydrogenase (LDH) and Creatine Kinase- MB (CK-MB) were examined by enzyme-linked immunosorbent assay. Cell viability was measured by MTT assay and the cell apoptosis was validated by flow cytometry. MicroRNA-124-3p (miR-124-3p), Signal Transducer and Activator of Transcription 3 (STAT3), Phosphoinositide 3-Kin.. View More»